AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Eisai Inc. and Merck known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Ad...Read more
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
Accelerating IVD Innovations
Not always perceived as the most exciting field as therapeutics, the diagnostics industry is gaining momentum and growing and changing just as fast. At a rapid pace with projected sales growth between 2012 and 2018 from $43.6 billion to $58.8 billion (CAGR of 5.1 per cent), the industry looks appealing (EvaluateMedtech). Despite global economic and industry challenges, in-vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry in some segments. Growth in emerging markets and next-wave emerging markets, particularly in the Asia-Pacific (APAC) region, are the most important factors in formulating future strategies.